Clinical characteristics, GAD antibody (GADA) and change of C-peptide in Korean young age of onset diabetic patients

C. W. Ahn, H. S. Kim, J. H. Nam, Y. D. Song, Sungkil Lim, K. R. Kim, H. C. Lee, K. B. Huh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aims: To investigate the association of clinical and immunological markers with diabetes classification in newly diagnosed young diabetic patients at disease onset. Methods: Eighty-two diabetic patients recruited within 1 year of onset (mean age 23.0 ± 7.1, M:F = 46:36) were divided into three groups, namely: a low fasting C-peptide (FC) level at baseline group (the low FC group (n = 14, FC < 0.18 nmol/l)), an intermediate FC group (n = 29, 0.18 nmol/l ≤ FC < 0.37 nmol/l), and a high FC group (n = 39, 0.37 nmol/l ≤ FC). Patients were reclassified at follow-up (mean follow-up period 3.7 ± 1.4 years) in the same manner as described above into low FC group (n = 31), intermediate FC group (n = 20), and high FC group (n = 31). The clinical characteristics and prevalence of GADA were compared. Results: Patients in the high FC group at baseline had a higher body mass index (BMI), a higher frequency of a family history of diabetes, a higher meal-stimulated C-peptide increment, a lower frequency of ketonuria, a lower frequency of history of diabetic ketoacidosis, and a lower frequency of insulin therapy at diagnosis than those in the low and intermediate FC groups at baseline. Insulin secretory capacity, which was represented by fasting C-peptide, was affected by BMI at diagnosis and the presence of GADA. All the patients of the low FC group on follow-up were finally classified as having Type 1 diabetes; moreover, the factors that determined the type of diabetes were lower BMI at onset, GADA positivity, insulin therapy, lower fasting C-peptide level and lower meal-stimulated C-peptide increment at initial admission. Conclusions: Our study suggests that follow-up involving C-peptide and GADA measurements in combination with clinical characteristics is useful for discriminating between the types of diabetes in these groups.

Original languageEnglish
Pages (from-to)227-233
Number of pages7
JournalDiabetic Medicine
Volume19
Issue number3
DOIs
Publication statusPublished - 2002 May 4

Fingerprint

C-Peptide
Age of Onset
Fasting
Antibodies
Body Mass Index
Meals
Insulin
Insulin Antibodies
Diabetic Ketoacidosis
Ketosis

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Ahn, C. W. ; Kim, H. S. ; Nam, J. H. ; Song, Y. D. ; Lim, Sungkil ; Kim, K. R. ; Lee, H. C. ; Huh, K. B. / Clinical characteristics, GAD antibody (GADA) and change of C-peptide in Korean young age of onset diabetic patients. In: Diabetic Medicine. 2002 ; Vol. 19, No. 3. pp. 227-233.
@article{c66e35ddccee45d093ed04bf317130e8,
title = "Clinical characteristics, GAD antibody (GADA) and change of C-peptide in Korean young age of onset diabetic patients",
abstract = "Aims: To investigate the association of clinical and immunological markers with diabetes classification in newly diagnosed young diabetic patients at disease onset. Methods: Eighty-two diabetic patients recruited within 1 year of onset (mean age 23.0 ± 7.1, M:F = 46:36) were divided into three groups, namely: a low fasting C-peptide (FC) level at baseline group (the low FC group (n = 14, FC < 0.18 nmol/l)), an intermediate FC group (n = 29, 0.18 nmol/l ≤ FC < 0.37 nmol/l), and a high FC group (n = 39, 0.37 nmol/l ≤ FC). Patients were reclassified at follow-up (mean follow-up period 3.7 ± 1.4 years) in the same manner as described above into low FC group (n = 31), intermediate FC group (n = 20), and high FC group (n = 31). The clinical characteristics and prevalence of GADA were compared. Results: Patients in the high FC group at baseline had a higher body mass index (BMI), a higher frequency of a family history of diabetes, a higher meal-stimulated C-peptide increment, a lower frequency of ketonuria, a lower frequency of history of diabetic ketoacidosis, and a lower frequency of insulin therapy at diagnosis than those in the low and intermediate FC groups at baseline. Insulin secretory capacity, which was represented by fasting C-peptide, was affected by BMI at diagnosis and the presence of GADA. All the patients of the low FC group on follow-up were finally classified as having Type 1 diabetes; moreover, the factors that determined the type of diabetes were lower BMI at onset, GADA positivity, insulin therapy, lower fasting C-peptide level and lower meal-stimulated C-peptide increment at initial admission. Conclusions: Our study suggests that follow-up involving C-peptide and GADA measurements in combination with clinical characteristics is useful for discriminating between the types of diabetes in these groups.",
author = "Ahn, {C. W.} and Kim, {H. S.} and Nam, {J. H.} and Song, {Y. D.} and Sungkil Lim and Kim, {K. R.} and Lee, {H. C.} and Huh, {K. B.}",
year = "2002",
month = "5",
day = "4",
doi = "10.1046/j.1464-5491.2002.00670.x",
language = "English",
volume = "19",
pages = "227--233",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "3",

}

Clinical characteristics, GAD antibody (GADA) and change of C-peptide in Korean young age of onset diabetic patients. / Ahn, C. W.; Kim, H. S.; Nam, J. H.; Song, Y. D.; Lim, Sungkil; Kim, K. R.; Lee, H. C.; Huh, K. B.

In: Diabetic Medicine, Vol. 19, No. 3, 04.05.2002, p. 227-233.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical characteristics, GAD antibody (GADA) and change of C-peptide in Korean young age of onset diabetic patients

AU - Ahn, C. W.

AU - Kim, H. S.

AU - Nam, J. H.

AU - Song, Y. D.

AU - Lim, Sungkil

AU - Kim, K. R.

AU - Lee, H. C.

AU - Huh, K. B.

PY - 2002/5/4

Y1 - 2002/5/4

N2 - Aims: To investigate the association of clinical and immunological markers with diabetes classification in newly diagnosed young diabetic patients at disease onset. Methods: Eighty-two diabetic patients recruited within 1 year of onset (mean age 23.0 ± 7.1, M:F = 46:36) were divided into three groups, namely: a low fasting C-peptide (FC) level at baseline group (the low FC group (n = 14, FC < 0.18 nmol/l)), an intermediate FC group (n = 29, 0.18 nmol/l ≤ FC < 0.37 nmol/l), and a high FC group (n = 39, 0.37 nmol/l ≤ FC). Patients were reclassified at follow-up (mean follow-up period 3.7 ± 1.4 years) in the same manner as described above into low FC group (n = 31), intermediate FC group (n = 20), and high FC group (n = 31). The clinical characteristics and prevalence of GADA were compared. Results: Patients in the high FC group at baseline had a higher body mass index (BMI), a higher frequency of a family history of diabetes, a higher meal-stimulated C-peptide increment, a lower frequency of ketonuria, a lower frequency of history of diabetic ketoacidosis, and a lower frequency of insulin therapy at diagnosis than those in the low and intermediate FC groups at baseline. Insulin secretory capacity, which was represented by fasting C-peptide, was affected by BMI at diagnosis and the presence of GADA. All the patients of the low FC group on follow-up were finally classified as having Type 1 diabetes; moreover, the factors that determined the type of diabetes were lower BMI at onset, GADA positivity, insulin therapy, lower fasting C-peptide level and lower meal-stimulated C-peptide increment at initial admission. Conclusions: Our study suggests that follow-up involving C-peptide and GADA measurements in combination with clinical characteristics is useful for discriminating between the types of diabetes in these groups.

AB - Aims: To investigate the association of clinical and immunological markers with diabetes classification in newly diagnosed young diabetic patients at disease onset. Methods: Eighty-two diabetic patients recruited within 1 year of onset (mean age 23.0 ± 7.1, M:F = 46:36) were divided into three groups, namely: a low fasting C-peptide (FC) level at baseline group (the low FC group (n = 14, FC < 0.18 nmol/l)), an intermediate FC group (n = 29, 0.18 nmol/l ≤ FC < 0.37 nmol/l), and a high FC group (n = 39, 0.37 nmol/l ≤ FC). Patients were reclassified at follow-up (mean follow-up period 3.7 ± 1.4 years) in the same manner as described above into low FC group (n = 31), intermediate FC group (n = 20), and high FC group (n = 31). The clinical characteristics and prevalence of GADA were compared. Results: Patients in the high FC group at baseline had a higher body mass index (BMI), a higher frequency of a family history of diabetes, a higher meal-stimulated C-peptide increment, a lower frequency of ketonuria, a lower frequency of history of diabetic ketoacidosis, and a lower frequency of insulin therapy at diagnosis than those in the low and intermediate FC groups at baseline. Insulin secretory capacity, which was represented by fasting C-peptide, was affected by BMI at diagnosis and the presence of GADA. All the patients of the low FC group on follow-up were finally classified as having Type 1 diabetes; moreover, the factors that determined the type of diabetes were lower BMI at onset, GADA positivity, insulin therapy, lower fasting C-peptide level and lower meal-stimulated C-peptide increment at initial admission. Conclusions: Our study suggests that follow-up involving C-peptide and GADA measurements in combination with clinical characteristics is useful for discriminating between the types of diabetes in these groups.

UR - http://www.scopus.com/inward/record.url?scp=0036229274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036229274&partnerID=8YFLogxK

U2 - 10.1046/j.1464-5491.2002.00670.x

DO - 10.1046/j.1464-5491.2002.00670.x

M3 - Article

C2 - 11918625

AN - SCOPUS:0036229274

VL - 19

SP - 227

EP - 233

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 3

ER -